[CAS NO. 1628428-01-2] PKRactivator3
PRODUCTS SPECIFICATIONS [1628428-01-2]
DESCRIPTION [1628428-01-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 468.57 |
| Molecular Formula | C24H28N4O4S |
| SMILES | N1C2C(=C(S(NC3=CC=C(C(N4CCC(O)(CC(C)C)CC4)=O)C=C3)(=O)=O)C=CC=2)N=CC=1 |
Summary
PKR-IN-2 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160. PKR-IN-2 can be used for the research of PKR function related diseases, including cancer , diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia [1] .
IC50 & Target
PKR [1]
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 106.71 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1342 mL | 10.6708 mL | 21.3415 mL |
| 5 mM | 0.4268 mL | 2.1342 mL | 4.2683 mL |
| 10 mM | 0.2134 mL | 1.0671 mL | 2.1342 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.34 mM); Clear solution